PZRXQ (PhaseRx) DeferredTaxAndRevenue: $0.00 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx DeferredTaxAndRevenue?

PhaseRx PZRXQ -99.00% DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2017.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

PhaseRx's current deferred tax and revenue for the quarter that ended in Sep. 2017 was $0.00 Mil.

PhaseRx DeferredTaxAndRevenue Related Terms

PhaseRx DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for PhaseRx's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx DeferredTaxAndRevenue Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
DeferredTaxAndRevenue
0.57 0.05 0.00

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
PhaseRx (PZRXQ) has a DeferredTaxAndRevenue of $0.00 Mil as of Sep. 2017. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on PhaseRx.
Is PhaseRx's DeferredTaxAndRevenue too high?
PhaseRx's current DeferredTaxAndRevenue is $0.00 Mil.
How does PhaseRx's DeferredTaxAndRevenue compare to NSPX and HSTC?
PhaseRx's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on PhaseRx. PhaseRx's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.